Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Holding ARCT?
Track your performance easily
ARCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.30 - $45.00
Previous Close$15.48
Volume812.43K
Average Volume (3M)398.62K
Market Cap
$419.31M
Enterprise Value$208.12M
Total Cash (Recent Filing)$237.18M
Total Debt (Recent Filing)$25.99M
Price to Earnings (P/E)―
Beta3.16
Next Earnings
Mar 03, 2025EPS Estimate
-$0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding27,087,359
10 Day Avg. Volume493,181
30 Day Avg. Volume398,624
Standard Deviation0.32
R-Squared0.18
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.60
Price to Sales (P/S)2.61
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.28
Enterprise Value/Gross Profit1.25
Enterprise Value/Ebitda-3.54
Forecast
1Y Price Target
$65.00Price Target Upside319.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Arcturus Therapeutics News
PremiumCompany Announcements
Arcturus Therapeutics Reports Q3 2024 Financial Results and Milestones
Bulls Say, Bears Say
Bulls Say
Earnings And MilestonesThe 3Q24 earnings report was encouraging with confirmation of Kostaive sales in Japan via a $25M milestone from CSL.
Market PositionSuperior efficacy vs dominant player Comirnaty combined with CSL’s existing commercial footprint and extensive contracting experience could represent key advantages.
Vaccine ApprovalEMA’s human medicines committee recommended granting marketing authorization for ARCT/CSL’s partnered self-amplifying mRNA COVID vaccine Kostaive.
Bears Say
Anti-Vaccination InfluenceMeiji is reviewing its Kostaive strategy to reflect more risk than initially expected from the impact of Japanese anti-vaccination groups on vaccination rates.
Delays In Product ApprovalsThere is a slight delay in timing for ARCT-810 for OTC update and EU Kostaive approval, which were pushed back compared to previous expectations.
Safety And Tolerability IssuesKey risks to the rating and price target include unforeseen safety or tolerability issues with ARCT-154, ARCT-810, or ARCT-032.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $14.30 and its highest was $45.00 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Currently, no data Available
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 71 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$1.216 by $0.956.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics does not currently pay dividends.
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -$0.57.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 27,087,358 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$1.216. Following the earnings report the stock price went up 4.696%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Among the largest hedge funds holding Arcturus Therapeutics’s share is ARK Investment Management LLC. It holds Arcturus Therapeutics’s shares valued at 49M.
---
Arcturus Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.00 (319.90% Upside)
$65.00 (319.90% Upside)
Blogger Sentiment
Bullish
ARCT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 146.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.69%
12-Months-Change
Fundamentals
Return on Equity
-21.96%
Trailing 12-Months
Asset Growth
-19.01%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
---
ARCT Company Deck
---
ARCT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted the successful commercial launch of KOSTAIVE in Japan and positive clinical trial results, indicating significant progress in Arcturus' pipeline. However, financial challenges such as a decrease in revenue and a reported net loss, along with delays in data for the OTC program, were noted. Overall, the sentiment is balanced with notable achievements and ongoing challenges.Read More>---
ARCT Stock 12 Month Forecast
Average Price Target
$65.00
▲(319.90% Upside)
Technical Analysis
Best Analysts Covering ARCT
1 Year
1 Year Success Rate
3/20 ratings generated profit
1 Year Average Return
-32.02%
assigned a buy rating 5 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 15.00% of your transactions generating a profit, with an average return of -32.02% per trade.
---